BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.60), $0.05 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $208.9 million versus the consensus estimate of $216.61 million.

BioMarin Pharma sees FY2015 revenue of $880-900 million, versus prior guidance of $850-880 million and the consensus of $897.92 million.

“BioMarin has been extremely productive over the last three months with the start of our gene therapy clinical study in hemophilia A patients, the acquisition of the PKU franchise from Merck Serono and the sale of our talazoparib program to Medivation, Inc., just to name a few accomplishments,” said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin. “On the regulatory front, we look forward to our meeting on November 24th with the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to review the New Drug Application (NDA) for Kyndrisa. We continue to prepare for the potential near-term approval of Kyndrisa for the treatment of children with Duchenne muscular dystrophy, a devastating muscle wasting disease for which there is no approved therapy in the U.S.”

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.